EUVIMEDEUVIMED entdecken
Crossref

Splenic complications in pediatric sickle cell disease: A retrospective cohort review

Alex George, Shannon E Conneely, Ross Mangum iD, Titilope Fasipe, Philip J Lupo iD, Michael E Scheurer

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Alex George und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Section of Hematology/Oncology, Wake Forest University School of Medicine and Brenner Children's Hospital, Winston-Salem, N…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hydroxyurea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To delineate the natural history of splenic complications other than loss of splenic function in children with sickle cell disease (SCD), we performed a retrospective chart review of patients with SCD treated at the Texas Children's Hospital.

Methods

We determined the dates of diagnoses of splenic complications, the number of acute splenic sequestration crises (ASSC), and hydroxyurea treatment in pediatric patients with SCD. We also examined the association of hydroxyurea therapy with the onset and severity of ASSC.

Results

The cumulative prevalence of splenic complications was 24.7% for splenomegaly, 24.2% for ASSC, 9.6% for hypersplenism, and 5.6% for splenectomy. The cumulative prevalence of splenic complications was highest in patients with hemoglobin Sβ 0 (69.2%), intermediate in hemoglobin SS (33.3%), low in hemoglobin SC (9.0%), and non‐existent in hemoglobin Sβ + . The overall event rate of ASSC was 8.3 per 100 patient‐years. The event‐rate was 28.4 for hemoglobin Sβ 0 , 10.9 for hemoglobin SS, and 3.5 for hemoglobin SC. Patients with hemoglobin SS and hemoglobin Sβ 0 on hydroxyurea therapy had a significantly higher occurrence of ASSC than those who were not, with event rates of 14.2 and 3.1, respectively. The event rate was also higher for children who started hydroxyurea before age 2 years than for those who started after this age (19.8 and 9.2, respectively).

Conclusions

The prevalence and severity of splenic problems vary widely between different sickle cell genotypes, with hemoglobin Sβ 0 having the most severe complications. Hydroxyurea therapy is associated with increased incidence of ASSC, particularly when initiated before 2 years of age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellHydroxyureaHumansRetrospective StudiesChildMaleFemaleAdolescentChild, PreschoolSplenic DiseasesInfantSplenomegalyAntisickling AgentsSplenectomyPrevalence

Stichwörter der Autor:innen

acute splenic sequestration criseshydroxyureahypersplenismsickle cell diseasesplenectomysplenomegaly

Substanzen

HydroxyureaAntisickling Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Section of Hematology/Oncology, Wake Forest University School of Medicine and Brenner Children's Hospital, Winston-Salem, North Carolina, USA.
  • Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, USA.
  • Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, Arizona, USA.

ORCID-Profile: Ross Mangum, Philip J Lupo

Förderung

  • Novo Nordisk

Zitieren

APA

George, A., Conneely, S. E., Mangum, R., Fasipe, T., Lupo, P. J., & Scheurer, M. E. (2024). Splenic complications in pediatric sickle cell disease: A retrospective cohort review. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31219

Vancouver

George A, Conneely SE, Mangum R, Fasipe T, Lupo PJ, Scheurer ME. Splenic complications in pediatric sickle cell disease: A retrospective cohort review. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31219

BibTeX
@article{George2024,
  author = {George, Alex and Conneely, Shannon E and Mangum, Ross and Fasipe, Titilope and Lupo, Philip J and Scheurer, Michael E},
  title = {Splenic complications in pediatric sickle cell disease: A retrospective cohort review},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31219}
}
Kostenlos starten →